229 related articles for article (PubMed ID: 35322583)
1. Renoprotective effect of additional sodium-glucose cotransporter 2 inhibitor therapy in type 2 diabetes patients with rapid decline and preserved renal function.
Sada K; Hidaka S; Kashima J; Morita M; Sada K; Shibata H
J Diabetes Investig; 2022 Aug; 13(8):1330-1338. PubMed ID: 35322583
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes.
Miyoshi H; Kameda H; Yamashita K; Nakamura A; Kurihara Y
J Diabetes Investig; 2019 Nov; 10(6):1510-1517. PubMed ID: 31026373
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter 2 inhibitors in type 2 diabetes patients with renal function impairment slow the annual renal function decline, in a real clinical practice.
Hirai T; Kitada M; Monno I; Oda E; Hayashi Y; Shimada K; Takagaki Y; Ogura Y; Fujii M; Konishi K; Sakurai M; Nakagawa A; Koya D
J Diabetes Investig; 2021 Sep; 12(9):1577-1585. PubMed ID: 33417741
[TBL] [Abstract][Full Text] [Related]
4. Initiation of sodium-glucose cotransporter-2 inhibitors at lower HbA1c threshold attenuates eGFR decline in type 2 diabetes patients with and without cardiorenal disease: A propensity-matched cohort study.
Cheung JTK; Yang A; Wu H; Lau ESH; Shi M; Kong APS; Ma RCW; Luk AOY; Chan JCN; Chow E
Diabetes Res Clin Pract; 2023 Jan; 195():110203. PubMed ID: 36493912
[TBL] [Abstract][Full Text] [Related]
5. Initial Acute Decline in Estimated Glomerular Filtration Rate After Sodium-Glucose Cotransporter-2 Inhibitor in Patients With Chronic Kidney Disease.
Sugiyama S; Yoshida A; Hieshima K; Kurinami N; Jinnouchi K; Tanaka M; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T; Jinnouchi H
J Clin Med Res; 2020 Nov; 12(11):724-733. PubMed ID: 33224374
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Classes of Glucose-Lowering Medications on Renal Outcome in Type 2 Diabetes.
Takeuchi M; Ogura M; Minoura T; Inagaki N; Kawakami K
Mayo Clin Proc; 2020 Feb; 95(2):265-273. PubMed ID: 32029085
[TBL] [Abstract][Full Text] [Related]
7. Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors.
Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
Diabetes Obes Metab; 2021 Sep; 23(9):2077-2089. PubMed ID: 34047459
[TBL] [Abstract][Full Text] [Related]
8. Renal Protection and Safety of Sodium-glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.
Zhou T; Yao K; Xie Y; Lin Y; Wang J; Chen X
Curr Pharm Des; 2023; 29(21):1659-1670. PubMed ID: 37537933
[TBL] [Abstract][Full Text] [Related]
9. Parameters influencing renal response to SGLT2 inhibitors and GLP1 receptor agonists in type 2 diabetes patients with preserved renal function: a comparative, prospective study.
Biancalana E; Petralli G; Raggi F; Distaso MR; Piazza G; Rossi C; Tricò D; Solini A
J Endocrinol Invest; 2023 May; 46(5):991-999. PubMed ID: 36469293
[TBL] [Abstract][Full Text] [Related]
10. Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes.
Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
J Am Heart Assoc; 2021 Jun; 10(11):e020237. PubMed ID: 34013739
[TBL] [Abstract][Full Text] [Related]
11. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
[TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose co-transporter 2 inhibitors & glucagon-like peptide-1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients.
Mahmoud T; Yagan J; Hasan A; Gheith OA; Mostafa M; Rida S; El-Serwi N; Shaker M; Khalid M
Clin Transplant; 2023 Dec; 37(12):e15144. PubMed ID: 37755118
[TBL] [Abstract][Full Text] [Related]
13. Effect of sodium-glucose cotransporter 2 inhibitors on the rate of decline in kidney function: A systematic review and meta-analysis.
Duo Y; Gao J; Yuan T; Zhao W
J Diabetes; 2023 Jan; 15(1):58-70. PubMed ID: 36610036
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience.
Tumminia A; Graziano M; Vinciguerra F; Lomonaco A; Frittita L
Prim Care Diabetes; 2021 Apr; 15(2):283-288. PubMed ID: 33129749
[TBL] [Abstract][Full Text] [Related]
15. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
[TBL] [Abstract][Full Text] [Related]
16. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis.
Wang C; Zhou Y; Kong Z; Wang X; Lv W; Geng Z; Wang Y
Diabetes Obes Metab; 2019 Apr; 21(4):1018-1026. PubMed ID: 30565382
[TBL] [Abstract][Full Text] [Related]
17. The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors.
Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
Cardiovasc Diabetol; 2021 Aug; 20(1):167. PubMed ID: 34399757
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice.
Murashima M; Tanaka T; Kasugai T; Tomonari T; Ide A; Ono M; Mizuno M; Suzuki T; Hamano T
J Diabetes Investig; 2022 Apr; 13(4):638-646. PubMed ID: 34797947
[TBL] [Abstract][Full Text] [Related]
19. Concomitant treatment with insulin and sodium-glucose cotransporter 2 inhibitors was associated with the renal composite outcome in Japanese patients with type 2 diabetes and chronic kidney disease: A propensity score-matched analysis.
Toyoda M; Saito N; Kimura M; Hatori N; Tamura K; Miyakawa M; Sato K; Kanamori A; Kobayashi K
J Diabetes Investig; 2022 Sep; 13(9):1520-1527. PubMed ID: 35524473
[TBL] [Abstract][Full Text] [Related]
20. Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure.
Nakagaito M; Imamura T; Joho S; Ushijima R; Nakamura M; Kinugawa K
BMC Cardiovasc Disord; 2021 Jul; 21(1):347. PubMed ID: 34289813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
